Naloxegol

CHEMBL2219418 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

651.8 g/mol

LogP

-1.0

Phase

4

This medication is used to treat opioid-induced constipation in adults taking opioid pain medicines for non-cancer pain. It works by blocking opioid receptors specifically in the gut without affecting pain relief in the rest of the body, allowing normal bowel function to resume.

الوزن الجزيئي

651,8000 g/mol

LogP

-1,00

TPSA

127,00 Å²

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

آلية العمل

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5

InChI

InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1

Molecular Formula

C34H53NO11

HBD / HBA

2 / 12

الروابط القابلة للدوران

24

الذرات الثقيلة

46

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This medication is used to treat opioid-induced constipation in adults taking opioid pain medicines for non-cancer pain. It works by blocking opioid receptors specifically in the gut without affecting pain relief in the rest of the body, allowing normal bowel function to resume.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Naloxegol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2219418. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 56959087. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Naloxegol على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C34H53NO11
المرادفات: 1

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.